Figure S2 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer

Daniela Conticelli; Marco Volante; Filippo Pietrantonio; Claudia Orrù; Martina Olivero; Alessia Nottegar; Felice Borghi; Gian Luca Baiocchi; Giovanni Crotti; Uberto Fumagalli Romario; Giovanni De Manzoni; Rossella Reddavid; Roberta Porporato; Dinçer Kılıç; Rebecca Ghione; Erika Calabrò; Russell Petty; Simona Corso; Silvia Giordano; Cristina Migliore

doi:10.1158/0008-5472.29918906

Key Points

Cross‐sensitivity among EGFR targeting drugs was observed, revealing important implications for treatment.
EGFR inhibition response was linked to specific biomarkers, with AREG and EREG being particularly predictive.
Analysis utilized primary cells from gastroesophageal cancer patients to assess drug effectiveness.
These findings suggest the need for personalized approaches in treating gastroesophageal cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis showed cross‐sensitivity among EGFR targeting drugs in gastroesophageal cancer, indicating potential for improved treatment strategies.

Abstract

Cross‐sensitivity of GEA primary cells among EGFR targeting drugs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Conticelli et al. (2025) studied this question.

synapsesocial.com/papers/68af56faad7bf08b1eadd17f https://doi.org/10.1158/0008-5472.29918906

View Full Paper

Ask AI

Bookmark

Share

Figure S2 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Figure S2 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers